{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:45:19Z","timestamp":1791477919994,"version":"4.3.4"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>New studies have further strengthened existing evidence relating the use of biological drugs to serious infections. The risk does not seem to be any different with short-term or long-term use. There is still a lack of conclusive studies identifying biomarkers, but it is plausible that the drugs have direct effects on cytokines and cell activity and then serious infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The frequent infections of patients with RA may be due to the disease itself (altered immunological function, disability, immobility, joint surgery), extra-articular manifestations or DMARDs, immunosuppressants and steroids. The use of biological drugs lead to the development of serious infections including tuberculosis. Patients should be informed of their increased risk, and physicians need to be aware of these complications and how to treat them.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000389","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T15:03:15Z","timestamp":1492527795000},"page":"323-330","source":"Crossref","is-referenced-by-count":51,"title":["Infections in rheumatoid arthritis"],"prefix":"10.1097","volume":"29","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[{"name":"IRCCS Galeazzi Orthopedic Institute, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio Francesco","family":"Masala","sequence":"additional","affiliation":[{"name":"Orthopedic and Trauma Unit, Santissima Trinit\u00e0 Hospital, Cagliari"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"di Franco","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Internal Medicine and Medical Specialities, La Sapienza University of Rome, Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, L. Sacco University Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard.61.11.994","article-title":"Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study","volume":"61","author":"Mikuls","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/art.1780140119","article-title":"Infections in rheumatoid arthritis","volume":"14","author":"Baum","year":"1971","journal-title":"Arthritis Rheum"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study","volume":"9","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R5-20230828","first-page":"S67","article-title":"Infections and treatment of patients with rheumatic diseases","volume":"26","author":"Atzeni","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","article-title":"Rheumatoid arthritis","volume":"24","author":"Carmona","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.53.4.224","article-title":"Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate","volume":"53","author":"van der Veen","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Antirheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/ajrccm.150.1.8025760","article-title":"Opportunistic infection during treatment with low dose methotrexate","volume":"150","author":"LeMense","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-20230828","first-page":"2201","article-title":"Leflunomide-associated infections in rheumatoid arthritis","volume":"34","author":"Jenks","year":"2007","journal-title":"J Rheumatol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard.60.3.214","article-title":"Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery","volume":"60","author":"Grennan","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.23003","article-title":"The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis","volume":"57","author":"Edwards","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","article-title":"Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis","volume":"29","author":"Lahiri","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e3283025ec2","article-title":"Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies","volume":"220","author":"Keane","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1127\/0003-5548\/2014\/0392","article-title":"Human biological research since 2006 at the Christian-Albrechts-University in Kiel: aging, chronobiology, and high altitude adaptation","volume":"71","author":"Dittmar","year":"2014","journal-title":"Anthropol Anz"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatol Oxford"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"(SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R28-20230828","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection: United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R29-20230828","first-page":"1212","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"4","author":"Arkema","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","article-title":"Efficacy and safety of antitumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study","volume":"38","author":"Filippini","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"R36-20230828","first-page":"61704","article-title":"The risk of serious infection with biologics in treating patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"6736","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/annrheumdis-2012-202228","article-title":"Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK","volume":"72","author":"Davies","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers","volume":"84","author":"de La Forest Divonne","year":"2017","journal-title":"Joint Bone Spine"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor a blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MCP.0b013e3283455c0b","article-title":"Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents","volume":"17","author":"Alvarez","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2165\/00003495-200969110-00002","article-title":"Endemic fungal infections in patients receiving tumor necrosis factor-\u03b1 inhibitor therapy","volume":"69","author":"Smith","year":"2009","journal-title":"Drugs"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cmi.2016.05.030","article-title":"Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications","volume":"22","author":"Liao","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.berh.2015.09.004","article-title":"Arthroplasty in patients with established rheumatoid arthritis (RA): mitigating risks and optimizing outcomes","volume":"29","author":"Goodman","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMcp0905029","article-title":"Clinical practice. Infection associated with prosthetic joints","volume":"361","author":"Del Pozo","year":"2009","journal-title":"N Engl J Med"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1574-695X.2012.00938.x","article-title":"Pathogenesis and treatment concepts of orthopaedic biofilm infections","volume":"65","author":"Zimmerli","year":"2012","journal-title":"FEMS Immunol Med Microbiol"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/fmb.14.64","article-title":"Biofilms in peri prosthetic orthopedic infections","volume":"9","author":"Mc Conoughey","year":"2014","journal-title":"Future Microbiol"},{"key":"R48-20230828","first-page":"573","article-title":"Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis","volume":"55","author":"Goodman","year":"2016","journal-title":"Rheumatology(Oxford)"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00296-011-2040-6","article-title":"Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence","volume":"3","author":"Goh","year":"2012","journal-title":"Rheumatol Int"},{"key":"R51-20230828","article-title":"Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha","author":"Mabille","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R52-20230828","first-page":"164","article-title":"Infections and biological therapy in patients with rheumatic diseases","volume":"18","author":"Atzeni","year":"2016","journal-title":"IMAJ"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","article-title":"Risk of herpes\/herpes zoster during antitumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis","volume":"81","author":"Che","year":"2014","journal-title":"Joint Bone Spine"},{"key":"R54-20230828","first-page":"1","article-title":"Prevention of herpes zoster","volume":"50","author":"Harpaz","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","article-title":"Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"R58-20230828","first-page":"926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"Vigan\u00f2","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","article-title":"Epidemiology of hepatitis C virus infection","volume":"13","author":"Alter","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","article-title":"Long-term safety of abatacecpt in patients with rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoim Rev"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"(Suppl 2)","key":"R66-20230828","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2011-201036","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2008.090068","article-title":"Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab","volume":"68","author":"Hirao","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2014.912273","article-title":"Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy","volume":"14","author":"Vigan\u00f2","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3899\/jrheum.151105","article-title":"Low risk of hepatitis B virus reactivation in HBsAgnegative\/Anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study","volume":"43","author":"Varisco","year":"2016","journal-title":"J Rheumatol"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis patients with serological evidence of past or present hepatitis B infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R77-20230828","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmii.2011.12.020","article-title":"Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis","volume":"46","author":"Lin","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2011.07.005","article-title":"Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature","volume":"11","author":"Ferri","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/RHU.0b013e3181f4cd92","article-title":"Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection","volume":"16","author":"Mahajan","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/rheumatology\/kes051","article-title":"Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C. infection","volume":"51","author":"Dragonas","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:38:20Z","timestamp":1693201100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000389","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}